Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 5/20 | 0.41 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 3/20 | 0.37 |
| ▸ | CDK4 | P11802 | 2/20 | 0.37 |
| ▸ | CCND1 | P24385 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 5/20 | 0.37 |
| ▸ | KRAS | P01116 | 4/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | PLK1 | P53350 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5325131 | 0.95 | SOS1 (0.40) | SOS1CCNE2CCNE1CDK2CDK4 | |
| SCHEMBL12792113 | 0.90 | CCNE2 (0.41) | SOS1CCNE2CCNE1CDK2CDK4 | |
| SCHEMBL12792077 | 0.90 | CCNE2 (0.41) | SOS1CCNE2CCNE1CDK2CDK4 | |
| SCHEMBL3066318 | 0.87 | MTNR1A (0.35) | ALDH1A1TP53MAPTHPGDCA9 | |
| SCHEMBL3073070 | 0.82 | ADORA2A (0.40) | ALDH1A1TP53MAPT | |
| SCHEMBL3081959 | 0.78 | SOS1 (0.42) | SOS1EGFRKRASAURKARPS6KB1 | |
| SCHEMBL3084379 | 0.77 | CA1 (0.33) | ALDH1A1 | |
| SCHEMBL1304599 | 0.77 | MTNR1A (0.41) | ALDH1A1KDM4EMAPT | |
| SCHEMBL3072846 | 0.77 | GAA (0.33) | ALDH1A1KDM4EHPGDGPR55 | |
| SCHEMBL5325178 | 0.73 | MAPT (0.34) | MAPTGPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790882-B2 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick M. (CH) | 2010-09-07 | — | — | US | disclosed |
| EP-1773853-A1 | MONOPHOSPHINE COMPOUNDS, TRANSITION METAL COMPLEXES THEREOF AND PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS USING THE COMPLEXES AS ASYMMETRIC CATALYSTS | Sumitomo Chemical Company, Limited (JP) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121157-A1 | MONOPHOSPHINE COMPOUNDS, TRANSITION METAL COMPLEXES THEREOF AND PRODUCTION OF OPTICALLY ACTIVE COMPOUNDS USING THE COMPLEXES AS ASYMMETRIC CATALYSTS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | Carreira, Erick (CH) | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277772-A1 | Monophosphine compound, transition metal complex thereof and production method of optically active compound using the complex as asymmetric catalyst | C1R, ARL1, C5 | SOS1 1644/4885CCNE2 860/4885CCNE1 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.